Aberdeen Group plc - 31 Dec 2025 SCHEDULE 13G Report for Quoin Pharmaceuticals, Ltd. American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share (QNRX)

Filing Manager
Aberdeen Group plc
Reporting Manager
Aberdeen Group plc
Security
Quoin Pharmaceuticals, Ltd. American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share
Symbol
QNRX
Shares outstanding
838,926 shares
Disclosed Ownership
75,000 shares
Ownership
8.9%
Form type
SCHEDULE 13G
Filing time
28 Jan 2026, 11:05:39 UTC
Date of event
31 Dec 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Aberdeen Group plc disclosed 8.9% ownership in Quoin Pharmaceuticals, Ltd. American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share (QNRX) on 31 Dec 2025."

Quick Takeaways

  • Aberdeen Group plc filed SCHEDULE 13G for Quoin Pharmaceuticals, Ltd. American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share (QNRX).
  • Disclosed ownership: 8.9%.
  • Date of event: 31 Dec 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 28 Jan 2026, 11:05.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Aberdeen Group plc 8.9% 75,000 0 75,000 J. Clarke Jenny Clarke/Major Shareholding Reporting Analyst
abrdn Inc. 8.9% 75,000 0 75,000 J. Clarke Jenny Clarke/Major Shareholding Reporting Analyst

Sponsored